EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia

Chelsea Vrana, Matthew Zhang iD, Max Rochette, Michelle Alozie, Hailey Oviedo, Alan Gonzalez, Jaden Sherman, Barry Zorman, Pavel Sumazin, Karen R Rabin iD, Jacob J Junco iD

PLOS One · 17.06.2025 · 20 (6) · e0324443

DOI: 10.1371/journal.pone.0324443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 17.06.2025. Verfasst von Chelsea Vrana und 10 weiteren Autor:innen. Beteiligte Einrichtung: Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Piperidines, Cytokines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ladies Leukemia League, Lynch Family, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel agents targeting upregulated signaling pathways are needed to improve outcomes in T-cell acute lymphoblastic leukemia (T-ALL), since conventional cytotoxic chemotherapy regimens have reached the limits of tolerability. We identified upregulated, targetable signaling pathways common to both human T-ALL samples and a Kras LSL-G12D/+ . Mb1 Cre/+ murine model of T-ALL. We found the NAMPT inhibitor FK866 had the greatest cytotoxicity of a panel of small molecule inhibitors tested in human and mouse T-ALL cell lines, and in patient derived xenograft (PDX)-expanded T-ALL patient samples. We subsequently tested FK866 in vivo in PDX mouse models of T-ALL, and found that it significantly reduced the peripheral blood disease burden and prolonged the survival of leukemic mice (median survival of 60.5 vs 21 days, p = 0.0007). This screen for targetable pathways in T-ALL generated in vitro and in vivo preclinical data supporting NAMPT inhibition as a promising strategy for the treatment of T-ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nicotinamide PhosphoribosyltransferasePrecursor T-Cell Lymphoblastic Leukemia-LymphomaPiperidinesCytokinesAcrylamidesAnimalsHumansMiceCell Line, TumorXenograft Model Antitumor AssaysSignal Transduction

Substanzen

Nicotinamide PhosphoribosyltransferasePiperidinesCytokinesAcrylamidesN-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamidenicotinamide phosphoribosyltransferase, human

Autor:innen und Institutionen

  • Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States of America.

ORCID-Profile: Matthew Zhang, Karen R Rabin, Jacob J Junco

Förderung

  • Ladies Leukemia League
  • Lynch Family
  • NIH
  • CPRIT

Zitieren

APA

Vrana, C., Zhang, M., Rochette, M., Alozie, M., Oviedo, H., Gonzalez, A., Sherman, J., Zorman, B., Sumazin, P., Rabin, K. R., & Junco, J. J. (2025). Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia. PLOS One, 20(6), e0324443. https://doi.org/10.1371/journal.pone.0324443

Vancouver

Vrana C, Zhang M, Rochette M, Alozie M, Oviedo H, Gonzalez A, et al. Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia. PLOS One. 2025;20(6):e0324443. doi:10.1371/journal.pone.0324443

BibTeX
@article{Vrana2025,
  author = {Vrana, Chelsea and Zhang, Matthew and Rochette, Max and Alozie, Michelle and Oviedo, Hailey and Gonzalez, Alan and Sherman, Jaden and Zorman, Barry and Sumazin, Pavel and Rabin, Karen R and Junco, Jacob J},
  title = {Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {6},
  pages = {e0324443},
  doi = {10.1371/journal.pone.0324443}
}
Kostenlos starten →